A randomised trial comparing the safety and efficacy of the Zoladex 10.8 mg depot, administered every 12 weeks, to that of the Zoladex 23,6 mg depot, administered every 4 weeks, in patients with advanced prostate cancer
Publication year
1995Source
Medisch Contact, 27, 1, (1995), pp. 43-46ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Urology
Journal title
Medisch Contact
Volume
vol. 27
Issue
iss. 1
Page start
p. 43
Page end
p. 46
This item appears in the following Collection(s)
- Academic publications [238586]
- Faculty of Medical Sciences [90409]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.